Weinshenker BG - Search Results

1

Wingerchuk DM, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Curr Treat Options Neurol. 2005 May;7(3):173-182. doi: 10.1007/s11940-005-0010-6. Curr Treat Options Neurol. 2005. PMID: 15814070

2

Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis.

Weinshenker BG, Wingerchuk DM, Liu Q, Bissonet AS, Schaid DJ, Sommer SS. Weinshenker BG, et al. Neurology. 1997 Aug;49(2):378-85. doi: 10.1212/wnl.49.2.378. Neurology. 1997. PMID: 9270565

3

A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis.

Wingerchuk D, Liu Q, Sobell J, Sommer S, Weinshenker BG. Wingerchuk D, et al. Among authors: weinshenker bg. Neurology. 1997 Aug;49(2):626-8. doi: 10.1212/wnl.49.2.626. Neurology. 1997. PMID: 9270614

4

Clinical outcome measures and rating scales in multiple sclerosis trials.

Wingerchuk DM, Noseworthy JH, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Mayo Clin Proc. 1997 Nov;72(11):1070-9. doi: 10.4065/72.11.1070. Mayo Clin Proc. 1997. PMID: 9374984 Review.

5

Denaturation fingerprinting: two related mutation detection methods especially advantageous for high G + C regions.

Liu Q, Weinshenker BG, Wingerchuk DM, Sommer SS. Liu Q, et al. Among authors: weinshenker bg. Biotechniques. 1998 Jan;24(1):140-7. doi: 10.2144/98241rr01. Biotechniques. 1998. PMID: 9454966 Free article.

6

Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS.

Weinshenker BG, Hebrink D, Wingerchuk DM, Klein CJ, Atkinson E, O'Brien PC, McMurray CT. Weinshenker BG, et al. Neurology. 1999 Apr 22;52(7):1500-3. doi: 10.1212/wnl.52.7.1500. Neurology. 1999. PMID: 10227645

7

The clinical course of neuromyelitis optica (Devic's syndrome).

Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Neurology. 1999 Sep 22;53(5):1107-14. doi: 10.1212/wnl.53.5.1107. Neurology. 1999. PMID: 10496275

8

The natural history of multiple sclerosis: implications for trial design.

Wingerchuk DM, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Curr Opin Neurol. 1999 Jun;12(3):345-9. doi: 10.1097/00019052-199906000-00013. Curr Opin Neurol. 1999. PMID: 10499179 Review.

9

Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures.

Wingerchuk DM, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Neuroimaging Clin N Am. 2000 Nov;10(4):611-24 ,vii. Neuroimaging Clin N Am. 2000. PMID: 11359715 Review.

10

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.

Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA, Auger RG, Weinshenker BG, Dodick DW, Wingerchuk DM, Rodriguez M. Noseworthy JH, et al. Among authors: weinshenker bg. Neurology. 2001 Jun 12;56(11):1514-22. doi: 10.1212/wnl.56.11.1514. Neurology. 2001. PMID: 11402108 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

364 results

Search Page

Filters